Upon dissecting the interplay between CD276 expression levels and a range of clinical attributes in 133 BLCA specimens, we found no major disparities in CD276 expression based on sex, age, body mass index (BMI), history of hypertension (HBP), diabetes mellitus (DM), hyperlipidemia, tumor diameter, or the presence of multiple tumors (Table 2, p>0.05). The gene discussed is CD276; the disease is bladder transitional cell carcinoma.